The DOI matches its Crossref record.
Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity
Abstract
Water-soluble analogues of the antitumor alkaloid camptothecin (1) were prepared in which aminoalkyl groups were introduced into ring A or B. Most of the analogues were prepared by oxidation of camptothecin to 10-hydroxycamptothecin (2) followed by a Mannich reaction to give N-substituted 9-(aminomethyl)-10-hydroxycamptothecins (4-12) or by subsequent modification of Mannich product 4 (13, 15, 17, 19, 21). Others were obtained by modification of the hydroxyl group of 2 (25,26) or by total synthesis (35,42,43). These analogues, as well as some of their synthetic precursors, were evaluated for inhibition of topoisomerase I, cytotoxicity, and antitumor activity. Although there was not a quantitative correlation between these assays, compounds that inhibited topoisomerase I were also cytotoxic and demonstrated antitumor activity in vivo. Further evaluation of the most active water-soluble analogue led to the selection of 9-[(dimethylamino)methyl]-10-hydroxycamptothecin (4, SK&F 104864) for development as an antitumor agent. In addition to its water solubility, ease of synthesis from natural camptothecin, and high potency, 4 demonstrated broad-spectrum activity in preclinical tumor models and is currently undergoing Phase I clinical trials in cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Synergistic catalysis: A powerful synthetic strategy for new reaction development
Allen, A. E., & MacMillan, D. W. C. (2012) · Chemical Science · doi:10.1039/c2sc00907b · Cited by 1,201
Antibody–Drug Conjugates: An Emerging Concept in Cancer Therapy
Chari, R. V. J., Miller, M. L., & Widdison, W. C. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307628 · Cited by 930
Crystal Structures of Human Topoisomerase I in Covalent and Noncovalent Complexes with DNA
Redinbo, M. R., Stewart, L., Kuhn, P., Champoux, J. J., & Hol, W. G. J. (1998) · Science · doi:10.1126/science.279.5356.1504 · Cited by 889
Natural compounds for cancer treatment and prevention
Nobili, S., Lippi, D., Witort, E., Donnini, M., Bausi, L., Mini, E., & Capaccioli, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.01.017 · Cited by 780
Natural products as leads to anticancer drugs
Gordaliza, M. (2007) · Clinical and Translational Oncology · doi:10.1007/s12094-007-0138-9 · Cited by 701
Topoisomerases as anticancer targets
Delgado, J. L., Hsieh, C.-M., Chan, N.-L., & Hiasa, H. (2018) · Biochemical Journal · doi:10.1042/bcj20160583 · Cited by 481
Ardizzoni, A., Hansen, H., Dombernowsky, P., Gamucci, T., Kaplan, S., Postmus, P., Giaccone, G., Schaefer, B., Wanders, J., & Verweij, J. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.2090 · Cited by 480
Cancer Therapies Utilizing the Camptothecins: A Review of the in Vivo Literature
Venditto, V. J., & Simanek, E. E. (2010) · Molecular Pharmaceutics · doi:10.1021/mp900243b · Cited by 452
Camptothecin: current perspectives
Thomas, C. J., Rahier, N. J., & Hecht, S. M. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2003.11.036 · Cited by 451
Self-citationNakada, T., Sugihara, K., Jikoh, T., Abe, Y., & Agatsuma, T. (2019) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c18-00744 · Cited by 442
Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway
Chaturvedi, P., Eng, W. K., Zhu, Y., Mattern, M. R., Mishra, R., Hurle, M. R., Zhang, X., Annan, R. S., Lu, Q., Faucette, L. F., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202925 · Cited by 423
Self-citationHoughton, P. J., Cheshire, P. J., Hallman, J. D., Lutz, L., Friedman, H. S., Danks, M. K., & Houghton, J. A. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00686188 · Cited by 401
Pizzolato, J. F., & Saltz, L. B. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13780-4 · Cited by 359
Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor.
Rowinsky, E. K., Grochow, L. B., Hendricks, C. B., Ettinger, D. S., Forastiere, A. A., Hurowitz, L. A., McGuire, W. P., Sartorius, S. E., Lubejko, B. G., & Kaufmann, S. H. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.4.647 · Cited by 353
Topoisomerase I inhibitors: Review and update
Rothenberg, M. L. (1997) · Annals of Oncology · doi:10.1023/a:1008270717294 · Cited by 306
Camptothecins: A Review of Their Chemotherapeutic Potential
Ulukan, H., & Swaan, P. W. (2002) · Drugs · doi:10.2165/00003495-200262140-00004 · Cited by 299
The long story of camptothecin: From traditional medicine to drugs
Martino, E., Della Volpe, S., Terribile, E., Benetti, E., Sakaj, M., Centamore, A., Sala, A., & Collina, S. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.12.085 · Cited by 296
Clinical Pharmacokinetics of Irinotecan
Chabot, G. G. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199733040-00001 · Cited by 282
Topoisomerase I inhibitors: topotecan and irenotecan
Creemers, G. J., Lund, B., & Verweij, J. (1994) · Cancer Treatment Reviews · doi:10.1016/0305-7372(94)90011-6 · Cited by 252
Microfluidic co-culture devices to assess penetration of nanoparticles into cancer cell mass
Jarvis, M., Arnold, M., Ott, J., Pant, K., Prabhakarpandian, B., & Mitragotri, S. (2017) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10079 · Cited by 32
Metadata
- Authors
- Kingsbury, W. D., Boehm, J. C., Jakas, D. R., Holden, K. G., Hecht, S. M., Gallagher, G., Caranfa, M. J., McCabe, F. L., Faucette, L. F., Johnson, R. K., & Hertzberg, R. P.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1991-01
- Volume
- 34
- Issue
- 1
- Pages
- 98-107
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1981987977
- Cited by
- 518
- References
- 0
- FWCI
- 5.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.